CardioDynamics’ BioZ
This article was originally published in The Gray Sheet
Executive Summary
Impedance cardiography (ICG) technology is associated with improved blood flow in 88% of heart failure patients when used to optimize programming of temporary, dual-chamber pacemakers, according to a study presented at the North American Society of Pacing and Electrophysiology meeting May 9 in San Diego. BioZ results also are closely correlated to more invasive, "gold standard" measures of cardiac output, "suggesting the former modality may have clinical utility in patients with heart failure," according to a separate study by Mark Drazner, MD, and Clyde Yancy, MD, University of Texas Southwestern Medical Center. Medtronic will co-develop bi-ventricular pacing applications for the device, according to an agreement announced in March...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.